Immunomedics Engages Greenhill & Co. as Strategic Advisor
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
UBS Raises Price Target on Greenhill & Co. (GHL) to $17; Reiterates Sell
October 25, 2016 9:10 AM EDTUBS reiterated a Sell rating on Greenhill & Co. (NYSE: GHL), and raised the price target to $17.00 (from $13.00), following the company's 3Q earnings report. GHL reported EPS of $0.41, missing consensus estimates of $0.42. 4Q16 EPS estimates go up by 43c to $0.53 due to a much higher near-term outlook for advisory revenue... More
